Esperion Announces the Appointment of Jay P. Shepard to Board of Directors
May 29, 2018 09:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 29, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 25, 2018 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 25, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Primary Endpoint
May 23, 2018 08:15 ET
|
Esperion Therapeutics, Inc.
— Study 3 Achieves Additional 26% LDL-C Lowering on Background of Maximally Tolerated LDL-C Lowering Therapy in Patients Considered Statin Intolerant —— Additional hsCRP Reduction of 25% —— Cumulative...
Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
May 22, 2018 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 22, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare Conference
May 10, 2018 08:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 10, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care Conference
May 04, 2018 16:01 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 04, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results
May 02, 2018 07:40 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 02, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Long-Term Safety Study of Bempedoic Acid
May 02, 2018 07:30 ET
|
Esperion Therapeutics, Inc.
— Met Primary Endpoint of Safety and Tolerability in Largest and Longest Duration Study —— Bempedoic Acid Achieved Additional 20% On-Treatment LDL-C Lowering on Background Maximally Tolerated Statin...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 13, 2018 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 13, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia
March 27, 2018 07:30 ET
|
Esperion Therapeutics, Inc.
— Study Met Primary Endpoint with 30% Additional LDL-C Lowering — — hsCRP Reduction of 34% — — Observed to be Safe and Well-Tolerated in This Study — — Conference Call and Webcast on Tuesday, March...